Deltex Medical narrowed operating losses in the first half and announce that it has added three additional accounts to its platform programme in the US.
The group said US probe revenues rose by 39% to £0.8m in the six months to the end of June and US probe revenues were greater than the UK for the first time. Platform accounts increased from 17 to 24 - and now stood at 27 following the latest additions.
International probe revenues were up 12% at £0.7m with total revenues up 19%: strongest growth from larger markets including France and South Korea.
UK probe revenues down 36% at £0.8m although there was an improved performance in July and August.
Operating losses fell by 20% to £1.7m (2015: £2.1m).
Chairman Nigel Keen said: "Deltex entered the second half of 2016 with growing traction and sales in the US market along with continued growth and momentum in our other export markets. Maintaining these established trends will see the Group return to growth despite the challenging UK domestic market.
"Moreover, Deltex has already done much of the work to create opportunities both for more rapid growth in the USA and other export markets and to stabilise our UK business.
"The growing sales traction, in the US and internationally, together with cost reductions already made, completed investment in margin improvement programmes and well advanced product development plans, mean the Group is making good progress towards its key objective of moving through the operating cash break-even point."
Separately, the group announced that its has added three additional accounts to its platform programme in the US. Two of the new platform accounts are in the company's North-East territory and the third in the Mid-West. They bring the total number of platform accounts to 27,